SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

AZD-8835

Cat. No.: HY-12869

CAS No.: 1620576-64-8

Molecular Formula: $C_{22}H_{31}N_9O_3$

Molecular Weight: 469.54

Target: PI3K

Pathway: PI3K/Akt/mTOR

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 12.5 mg/mL (26.62 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.1297 mL	10.6487 mL	21.2974 mL
	5 mM	0.4259 mL	2.1297 mL	4.2595 mL
	10 mM	0.2130 mL	1.0649 mL	2.1297 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 0.83 mg/mL (1.77 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 0.83 mg/mL (1.77 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 0.83 mg/mL (1.77 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

AZD8835 is a potent and selective inhibitor of PI3Kα and PI3Kδ with IC_{50}s of 6.2 and 5.7 nM, respectively.

IC_{50} & Target

PI3Kδ 5.7 nM (IC_{50})	PI3Kα 6.2 nM (IC_{50})	PI3Kα-H1047R 5.8 nM (IC_{50})	PI3Kα-E545K 6 nM (IC_{50})
PI3Kγ 90 nM (IC_{50})	PI3Kβ 431 nM (IC_{50})		

In Vitro	The selectivity profile of AZD8835 (Compound 25) among the class I PI3K isoforms is tested in enzyme and cell based assays. At the enzyme level, AZD8835 is a potent mixed inhibitor of PI3Kα (IC_{50} 6.2 nM) and PI3Kδ (IC_{50} 5.7 nM), with selectivity against PI3Kβ (IC_{50} 431 nM) and PI3Kγ (IC_{50} 90 nM). AZD8835 is also a potent inhibitor of the commonly occurring PI3Kα mutants, PI3Kα- E545K (IC_{50} 6 nM) and PI3Kα-H1047R (IC_{50} 5.8 nM). In cell-based assays assessing the ability to inhibit Akt phosphorylation, AZD8835 is a potent inhibitor in cells sensitive to PI3Kα inhibition (IC_{50} 57 nM in PIK3CA mutant human breast ductal carcinoma BT474 cell line) and in cells sensitive to PI3Kδ inhibition (IC_{50} 49 nM in Jeko-1 B cell line, but not to cells sensitive to PI3Kβ inhibition (IC_{50} 3.5 μM in PTEN null breast adenocarcinoma MDA-MB-468 cells) or to PI3Kγ inhibition (IC_{50} 530 nM in monocytic RAW264 cell line)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	AZD8835 (Compound 25) displays good solubility, good permeability and low turnover in hepatocytes from various species. As expected from the in vitro data, low in vivo clearance associated with high bioavailability is seen in both rat and dog. AZD8835 shows high exposure following oral administration to SCID mice (AUC: 137 μM.h and C_{max} 34 μM at 50 mg/kg p.o.) and is selected for further in vivo evaluation. In a pharmacodynamic experiment following chronic oral dosing (25 mg/kg b.i.d. or 6 mg/kg b.i.d. of AZD8835) in nude mice bearing mutant H1047R PI3Kα SKOV-3 tumour xenografts, target modulation is assessed by measuring Akt phosphorylation levels at Ser473 at 30 minutes and 8 hours. At both doses, strong inhibition of Akt phosphorylation is observed at the 30 minute timepoint. At 8 hours, significant inhibition is still seen at the 25 mg/kg dose, whereas no inhibition is seen at the lower dose of 6 mg/kg, consistent with the lower plasma concentrations observed[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Mol Cancer. 2023 Mar 30;22(1):64.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Barlaam B, Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers. Bioo

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA